GEN Exclusives

More »

GEN Podcasts

*Podcasts play in a pop-up window. Please make sure your pop-up blocker is off.

GEN’s editor in chief, John Sterling, interviews life science academic and biotech industry leaders on important research, technology, and trends. These podcasts will keep you informed with all the important details you need.

Gregory Lucier (Chairman and CEO of Invitrogen) and Catherine Mackey, Ph.D. (Senior Vice President of Pfizer Global Research and Development, La Jolla Laboratories), Leaders of the Conference Steering Committee, and Stephen Ferruolo (Partner at Goodwin Procter) and Alan Lewis, Ph.D. (President and CEO of Novocell), Heads of the Conference Program Committee, are interviewed by GEN's Editor-in-Chief, John Sterling.


BIO is billing its annual convention this year (June 17—20 in San Diego) as "The Global Event for Biotechnology." It's easy to see why. With the increased outsourcing of biotech activities, a concern over global IP issues, growing access to worldwide funding organizations, ongoing efforts directed at harmonizing global biotech regulations, and the cross-border movement of biotech scientists, technicians, lawyers, and business people, biotechnology has become a truly globalized industry.


During this week's GEN podcast, our panelists discuss how the globalization of the bioindustry has affected each of their businesses. They take a close look at the scientific and commercial impacts of the Internet on their companies and on the industry in general. The panel also explores ways in which varying governmental policies dictate how and where research is done and offers suggestions for dealing with complicated intellectual property issues that often vary from country to country.


In an era focusing on risk-reduced life science business models, the GEN panelists provide insights on the strategic decisions biotech firms need to make to add value, mitigate risk, and bring treatments for life threatening diseases to patients faster and cheaper than traditional life science companies. And with partnerships between biotech companies and big pharma on the rise, the panel talks about proactive strategies and tactics to improve the odds of success for both parties entering into an alliance.

Gregory Lucier (Chairman and CEO of Invitrogen) and Catherine Mackey, Ph.D. (Senior Vice President of Pfizer Global Research and Development, La Jolla Laboratories), Leaders of the Conference Steering Committee.

Stephen Ferruolo (Partner at Goodwin Procter) and Alan Lewis, Ph.D. (President and CEO of Novocell), Heads of the Conference Program Committee.



Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...

Unable to get Jobs Listings.

More »

GEN Poll

More » Poll Results »

Biosimilars

Compared to the original biologics, do you think biosimilars run the risks of being less effective and causing more side effects?